Altshuler Shaham
ESPR icon

Altshuler Shaham’s Esperion Therapeutics ESPR Stock Holding History

Altshuler Shaham’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-5,802
Closed -$420K – 226
2018
Q1 		$420K Sell
5,802
-5,578
-49% -$410K 0.06% 102
2017
Q4 		$749K Buy
+11,380
New +$613K 0.11% 70

Other funds holding ESPR

BB Biotech
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Pentwater Capital Management
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Credit Suisse
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Altshuler Shaham's ESPR Position: Q2 2018 in Review

Altshuler Shaham sold out of Esperion Therapeutics (ESPR) in Q2 2018, closing a stake of 5,802 shares — an estimated $420K sold.

Altshuler Shaham first reported a position in ESPR in Q4 2017 and held it in 2 quarters. The position peaked at $749K in Q4 2017. 156 funds tracked by Wall St. Rank hold ESPR as of Q2 2018.

  • Altshuler Shaham reported no remaining Esperion Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Altshuler Shaham sold 5,802 Esperion Therapeutics shares in Q2 2018, an estimated $420K.
  • Altshuler Shaham first reported a position in Esperion Therapeutics in Q4 2017 and held it in 2 quarters.
  • Altshuler Shaham's Esperion Therapeutics position peaked at $749K in Q4 2017.
  • 156 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2018.

Based on Altshuler Shaham's 13F filing for Q2 2018, filed 13 Aug 2018.